Literature DB >> 33849917

On the Increased Event Rate of Urinary Tract Infection and Pneumonia in CKD Patients Treated with Roxadustat for Anemia.

Theodoros Eleftheriadis1, Georgios Pissas2, Vassilios Liakopoulos2, Ioannis Stefanidis2.   

Abstract

Entities:  

Keywords:  T cell; immune response; infection; roxadustat anemia

Mesh：

Substances：

Year:  2021        PMID： 33849917      PMCID： PMC8259647          DOI： 10.1681/ASN.2021020204

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN： 1046-6673            Impact factor:   14.978


× No keyword cloud information.
  5 in total

Review 1.  Hypoxia-inducible factors in T lymphocyte differentiation and function. A Review in the Theme: Cellular Responses to Hypoxia.

Authors:  Jin-Hui Tao; Joseph Barbi; Fan Pan
Journal:  Am J Physiol Cell Physiol       Date:  2015-09-09       Impact factor: 4.249

2.  Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis.

Authors:  Nan Chen; Chuanming Hao; Bi-Cheng Liu; Hongli Lin; Caili Wang; Changying Xing; Xinling Liang; Gengru Jiang; Zhengrong Liu; Xuemei Li; Li Zuo; Laimin Luo; Jianqin Wang; Ming-Hui Zhao; Zhihong Liu; Guang-Yan Cai; Li Hao; Robert Leong; Chunrong Wang; Cameron Liu; Thomas Neff; Lynda Szczech; Kin-Hung P Yu
Journal:  N Engl J Med       Date:  2019-07-24       Impact factor: 91.245

3.  Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan.

Authors:  Tadao Akizawa; Manabu Iwasaki; Yusuke Yamaguchi; Yoshikatsu Majikawa; Michael Reusch
Journal:  J Am Soc Nephrol       Date:  2020-06-03       Impact factor: 10.121

4.  Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study.

Authors:  Steven Fishbane; Mohamed A El-Shahawy; Roberto Pecoits-Filho; Bui Pham Van; Mark T Houser; Lars Frison; Dustin J Little; Nicolas J Guzman; Pablo E Pergola
Journal:  J Am Soc Nephrol       Date:  2021-02-10       Impact factor: 10.121

5.  In Mixed Lymphocyte Reaction, the Hypoxia-Inducible Factor Prolyl-Hydroxylase Inhibitor Roxadustat Suppresses Cellular and Humoral Alloimmunity.

Authors:  Theodoros Eleftheriadis; Georgios Pissas; Athanasios Mavropoulos; Evdokia Nikolaou; Georgios Filippidis; Vassilios Liakopoulos; Ioannis Stefanidis
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2020-10-04       Impact factor: 4.291
  5 in total
  3 in total

Review 1.  Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease.

Authors:  Patrizia Natale; Suetonia C Palmer; Allison Jaure; Elisabeth M Hodson; Marinella Ruospo; Tess E Cooper; Deirdre Hahn; Valeria M Saglimbene; Jonathan C Craig; Giovanni Fm Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2022-08-25

2.  Authors' Reply.

Authors:  Steven Fishbane; Mohamed A El-Shahawy; Bui Pham Van; Dustin J Little
Journal:  J Am Soc Nephrol       Date:  2021-04-13       Impact factor: 14.978

3.  Risk of infection in roxadustat treatment for anemia in patients with chronic kidney disease: A systematic review with meta-analysis and trial sequential analysis.

Authors:  Shan Chong; Qiufen Xie; Tiantian Ma; Qian Xiang; Ying Zhou; Yimin Cui
Journal:  Front Pharmacol       Date:  2022-09-16       Impact factor: 5.988
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.